+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

HIV Disease Coverage Forecast and Market Analysis to 2024

  • ID: 4533538
  • Report
  • 717 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Market Snapshot
  • B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
  • TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
  • HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
  • Rapid uptake of TAF-based regimens in the US will protect Gilead’s revenues following TDF patent expiry.
  • B/F/TAF’s potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: HIV (Published on 22 December 2017)
Overview
Executive Summary
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Atripla
Product Profile (Late Stage): B/F/Taf
Product Profile: Complera
Product Profile (Late Stage): Dor/3Tc/Tdf
Product Profile: Descovy
Product Profile: Genvoya
Product Profile: Isentress
Product Profile: Juluca
Product Profile: Odefsey
Product Profile: Prezista Franchise
Product Profile: Reyataz Franchise
Product Profile: Stribild
Product Profile: Symtuza
Product Profile: Tivicay
Product Profile (Late Stage): Tivicay/Epivir
Product Profile: Triumeq
Product Profile: Truvada
Product Profile (Late Stage): Cabotegravir/Rilpivirine
Product Profile (Late Stage): Fostemsavir

TREATMENT: HIV (Published on 13 April 2018)
Overview
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Treatment Guidelines
Prescribing Trends
Unmet Needs In Hiv
Impact Of Generics

EPIDEMIOLOGY: HIV (Published on 25 January 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: HIV (Published on 22 December 2017)
Overview
Executive Summary
Product Overview
Product Profile: Atripla
Product Profile: Complera
Product Profile: Descovy
Product Profile: Genvoya
Product Profile: Isentress
Product Profile: Juluca
Product Profile: Odefsey
Product Profile: Prezista Franchise
Product Profile: Reyataz Franchise
Product Profile: Stribild
Product Profile: Symtuza
Product Profile: Tivicay
Product Profile: Triumeq
Product Profile: Truvada

PIPELINE: HIV (Published on 22 December 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): B/F/Taf
Product Profile (Late Stage): Dor/3Tc/Tdf
Product Profile (Late Stage): Tivicay/Epivir
Product Profile (Late Stage): Cabotegravir/Rilpivirine
Product Profile (Late Stage): Fostemsavir

LIST OF FIGURES
Figure 1: HIV – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for HIV
Figure 3: HIV total market value across the US and five major EU markets, by country, 2017-26
Figure 4: HIV total market value across the US and five major EU markets, by class, 2017-26
Figure 5: HIV sales in the US, 2017–26
Figure 6: HIV sales in the five major EU markets, by country, 2017–26
Figure 7: Sales of B/F/TAF compared to INSTI-based STRs and injections, by product, 2017–26
Figure 8: Sales of ViiV Healthcare’s oral two-drug regimens compared to B/F/TAF and Symtuza, by product, 2017–26
Figure 9: HIV sales across the US and five major EU markets, by company, 2017-26
Figure 10: The authors HIV forecast methodology
Figure 11: Price sources and calculations, by country
Figure 12: Atripla for HIV – SWOT analysis
Figure 13: The authors drug assessment summary of Atripla for HIV
Figure 14: The authors drug assessment summary of Atripla for HIV
Figure 15: Atripla sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 16: B/F/TAF for HIV – SWOT analysis
Figure 17: The authors drug assessment summary of B/F/TAF for HIV
Figure 18: The authors drug assessment summary of B/F/TAF for HIV
Figure 19: B/F/TAF sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 20: Complera for HIV – SWOT analysis
Figure 21: The authors drug assessment summary of Complera for HIV
Figure 22: The authors drug assessment summary of Complera for HIV
Figure 23: Complera sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 24: DOR/3TC/TDF for HIV – SWOT analysis
Figure 25: The authors drug assessment summary of DOR/3TC/TDF for HIV
Figure 26: The authors drug assessment summary of DOR/3TC/TDF for HIV
Figure 27: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 28: Descovy for HIV – SWOT analysis
Figure 29: The authors drug assessment summary of Descovy for HIV
Figure 30: The authors drug assessment summary of Descovy for HIV
Figure 31: Descovy sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 32: Genvoya for HIV – SWOT analysis
Figure 33: The authors drug assessment summary of Genvoya for HIV
Figure 34: The authors drug assessment summary of Genvoya for HIV
Figure 35: Genvoya sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 36: Isentress for HIV – SWOT analysis
Figure 37: The authors drug assessment summary of Isentress for HIV
Figure 38: The authors drug assessment summary of Isentress for HIV
Figure 39: Isentress sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 40: Juluca for HIV – SWOT analysis
Figure 41: The authors drug assessment summary of Juluca for HIV
Figure 42: The authors drug assessment summary of Juluca for HIV
Figure 43: Juluca sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 44: Odefsey for HIV – SWOT analysis
Figure 45: The authors drug assessment summary of Odefsey for HIV
Figure 46: The authors drug assessment summary of Odefsey for HIV
Figure 47: Odefsey sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 48: Prezista franchise for HIV – SWOT analysis
Figure 49: The authors drug assessment summary of Prezista franchise for HIV
Figure 50: The authors drug assessment summary of Prezista franchise for HIV
Figure 51: Prezista sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 52: Prezcobix sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 53: Reyataz franchise for HIV – SWOT analysis
Figure 54: The authors drug assessment summary of Reyataz franchise for HIV
Figure 55: The authors drug assessment summary of Reyataz franchise for HIV
Figure 56: Reyataz sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 57: Evotaz sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 58: Stribild for HIV – SWOT analysis
Figure 59: The authors drug assessment summary of Stribild for HIV
Figure 60: The authors drug assessment summary of Stribild for HIV
Figure 61: Stribild sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 62: Symtuza for HIV – SWOT analysis
Figure 63: The authors drug assessment summary of Symtuza for HIV
Figure 64: The authors drug assessment summary of Symtuza for HIV
Figure 65: Symtuza sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 66: Tivicay for HIV – SWOT analysis
Figure 67: The authors drug assessment summary of Tivicay for HIV
Figure 68: The authors drug assessment summary of Tivicay for HIV
Figure 69: Tivicay sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 70: Tivicay/Epivir for HIV – SWOT analysis
Figure 71: The authors drug assessment summary of Tivicay/Epivir for HIV
Figure 72: The authors drug assessment summary of Tivicay/Epivir for HIV
Figure 73: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 74: Triumeq for HIV – SWOT analysis
Figure 75: The authors drug assessment summary of Triumeq for HIV
Figure 76: The authors drug assessment summary of Triumeq for HIV
Figure 77: Triumeq sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 78: Truvada for HIV – SWOT analysis
Figure 79: The authors drug assessment summary of Truvada for HIV
Figure 80: The authors drug assessment summary of Truvada for HIV
Figure 81: Truvada sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 82: Cabotegravir/rilpivirine for HIV – SWOT analysis
Figure 83: The authors drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 84: The authors drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 85: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 86: Fostemsavir for HIV – SWOT analysis
Figure 87: The authors drug assessment summary of fostemsavir for HIV
Figure 88: The authors drug assessment summary of fostemsavir for HIV
Figure 89: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 90: Percentage of HIV prevalent population who are diagnosed and undiagnosed in the US and five major EU markets, by country
Figure 91: Percentage of the HIV-diagnosed population under physician care in the US and five major EU markets, by country
Figure 92: Breakdown of pharmacologically treated HIV patients in the US and five major EU markets, by line of therapy and country
Figure 93: Percentage of respondents in the US and five major EU markets who agree with initiating treatment in all patients, by country
Figure 94: Treatment status of HIV patients under physician care in the US and five major EU markets, by country
Figure 95: Top five brands used for the treatment of first-line HIV patients, by country
Figure 96: Top five regimens used for the treatment of first-line HIV patients, by country
Figure 97: Top five regimens used for the treatment of second-line HIV patients, by country
Figure 98: Top five brands used for the treatment of second-line HIV patients, by country
Figure 99: Top five regimens used for the treatment of third-line HIV patients, by country
Figure 100: Top five brands used for the treatment of third-line HIV patients, by country
Figure 101: Top five regimens used for the treatment of fourth-line and beyond HIV patients, by country
Figure 102: Top five brands used for the treatment of fourth-line and beyond HIV patients, by country
Figure 103: Relative importance of unmet needs in HIV treatment in the US and five major EU markets, by country
Figure 104: Physician views on potential adherence impact of breaking up FDCs in HIV in the US and five major EU markets, by country
Figure 105: Extent of physician comfort with breaking up FDCs to prescribe separate generic components in HIV in the US and five major EU markets, by country
Figure 106: Physician views on whether cost savings justify the breaking up of FDCs in HIV in the US and five major EU markets, by country
Figure 107: Atripla for HIV – SWOT analysis
Figure 108: The authors drug assessment summary of Atripla for HIV
Figure 109: The authors drug assessment summary of Atripla for HIV
Figure 110: Atripla sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 111: Complera for HIV – SWOT analysis
Figure 112: The authors drug assessment summary of Complera for HIV
Figure 113: The authors drug assessment summary of Complera for HIV
Figure 114: Complera sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 115: Descovy for HIV – SWOT analysis
Figure 116: The authors drug assessment summary of Descovy for HIV
Figure 117: The authors drug assessment summary of Descovy for HIV
Figure 118: Descovy sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 119: Genvoya for HIV – SWOT analysis
Figure 120: The authors drug assessment summary of Genvoya for HIV
Figure 121: The authors drug assessment summary of Genvoya for HIV
Figure 122: Genvoya sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 123: Isentress for HIV – SWOT analysis
Figure 124: The authors drug assessment summary of Isentress for HIV
Figure 125: The authors drug assessment summary of Isentress for HIV
Figure 126: Isentress sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 127: Juluca for HIV – SWOT analysis
Figure 128: The authors drug assessment summary of Juluca for HIV
Figure 129: The authors drug assessment summary of Juluca for HIV
Figure 130: Juluca sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 131: Odefsey for HIV – SWOT analysis
Figure 132: The authors drug assessment summary of Odefsey for HIV
Figure 133: The authors drug assessment summary of Odefsey for HIV
Figure 134: Odefsey sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 135: Prezista franchise for HIV – SWOT analysis
Figure 136: The authors drug assessment summary of Prezista franchise for HIV
Figure 137: The authors drug assessment summary of Prezista franchise for HIV
Figure 138: Prezista sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 139: Prezcobix sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 140: Reyataz franchise for HIV – SWOT analysis
Figure 141: The authors drug assessment summary of Reyataz franchise for HIV
Figure 142: The authors drug assessment summary of Reyataz franchise for HIV
Figure 143: Reyataz sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 144: Evotaz sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 145: Stribild for HIV – SWOT analysis
Figure 146: The authors drug assessment summary of Stribild for HIV
Figure 147: The authors drug assessment summary of Stribild for HIV
Figure 148: Stribild sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 149: Symtuza for HIV – SWOT analysis
Figure 150: The authors drug assessment summary of Symtuza for HIV
Figure 151: The authors drug assessment summary of Symtuza for HIV
Figure 152: Symtuza sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 153: Tivicay for HIV – SWOT analysis
Figure 154: The authors drug assessment summary of Tivicay for HIV
Figure 155: The authors drug assessment summary of Tivicay for HIV
Figure 156: Tivicay sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 157: Triumeq for HIV – SWOT analysis
Figure 158: The authors drug assessment summary of Triumeq for HIV
Figure 159: The authors drug assessment summary of Triumeq for HIV
Figure 160: Triumeq sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 161: Truvada for HIV – SWOT analysis
Figure 162: The authors drug assessment summary of Truvada for HIV
Figure 163: The authors drug assessment summary of Truvada for HIV
Figure 164: Truvada sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 165: B/F/TAF for HIV – SWOT analysis
Figure 166: The authors drug assessment summary of B/F/TAF for HIV
Figure 167: The authors drug assessment summary of B/F/TAF for HIV
Figure 168: B/F/TAF sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 169: DOR/3TC/TDF for HIV – SWOT analysis
Figure 170: The authors drug assessment summary of DOR/3TC/TDF for HIV
Figure 171: The authors drug assessment summary of DOR/3TC/TDF for HIV
Figure 172: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 173: Tivicay/Epivir for HIV – SWOT analysis
Figure 174: The authors drug assessment summary of Tivicay/Epivir for HIV
Figure 175: The authors drug assessment summary of Tivicay/Epivir for HIV
Figure 176: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 177: Cabotegravir/rilpivirine for HIV – SWOT analysis
Figure 178: The authors drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 179: The authors drug assessment summary of cabotegravir/rilpivirine for HIV
Figure 180: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2017–26
Figure 181: Fostemsavir for HIV – SWOT analysis
Figure 182: The authors drug assessment summary of fostemsavir for HIV
Figure 183: The authors drug assessment summary of fostemsavir for HIV
Figure 184: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: HIV sales across the US and five major EU markets, by company ($m), 2017-26
Table 2: Molecules and brands included in The authors patient-based HIV forecast
Table 3: Exchange rates used for calculating prices
Table 4: Infectious disease specialists surveyed for the HIV primary research study, 2017
Table 5: Atripla drug profile
Table 6: Atripla pivotal data in HIV
Table 7: Atripla sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 8: B/F/TAF drug profile
Table 9: B/F/TAF Phase III data in HIV
Table 10: B/F/TAF Phase III trials in HIV
Table 11: B/F/TAF sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 12: Complera drug profile
Table 13: Complera pivotal data in HIV
Table 14: Complera other late-phase trial data in HIV
Table 15: Complera sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 16: DOR/3TC/TDF drug profile
Table 17: DOR/3TC/TDF Phase III data in HIV
Table 18: DOR/3TC/TDF Phase III trials in HIV
Table 19: Doravirine Phase III trials in HIV
Table 20: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 21: Descovy drug profile
Table 22: Descovy pivotal data in HIV
Table 23: Descovy other late-phase trials in HIV
Table 24: Descovy sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 25: Genvoya drug profile
Table 26: Genvoya pivotal data in HIV
Table 27: Genvoya other late-phase data in HIV
Table 28: Genvoya ongoing late-phase trials in HIV
Table 29: Genvoya sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 30: Isentress drug profile
Table 31: Isentress pivotal data in HIV
Table 32: Isentress sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 33: Juluca drug profile
Table 34: Juluca Phase III data in HIV
Table 35: Juluca sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 36: Odefsey drug profile
Table 37: Odefsey pivotal data in HIV
Table 38: Odefsey other late-phase data in HIV
Table 39: Odefsey sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 40: Prezista drug profile
Table 41: Prezcobix drug profile
Table 42: Prezista pivotal data in HIV
Table 43: Prezista pivotal data in HIV
Table 44: Prezista sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 45: Prezcobix sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 46: Reyataz drug profile
Table 47: Evotaz drug profile
Table 48: Reyataz pivotal data in HIV
Table 49: Reyataz other late-phase data in HIV
Table 50: Reyataz other late-phase data in HIV
Table 51: Reyataz sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 52: Evotaz sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 53: Stribild drug profile
Table 54: Stribild pivotal data in HIV
Table 55: Stribild other late-phase data in HIV
Table 56: Stribild sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 57: Symtuza drug profile
Table 58: Symtuza pivotal data in HIV
Table 59: Symtuza sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 60: Tivicay drug profile
Table 61: Tivicay pivotal data in HIV
Table 62: Tivicay pivotal data in HIV
Table 63: Tivicay ongoing late-phase clinical trials in HIV
Table 64: Tivicay sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 65: Tivicay/Epivir drug profile
Table 66: Tivicay/Epivir Phase III trials in HIV
Table 67: Tivicay/Epivir Phase II data in HIV
Table 68: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 69: Triumeq drug profile
Table 70: Triumeq pivotal data in HIV
Table 71: Triumeq other late-phase data in HIV
Table 72: Triumeq sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 73: Truvada drug profile
Table 74: Truvada pivotal data in HIV
Table 75: Truvada pivotal data in HIV
Table 76: Truvada sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 77: Cabotegravir/rilpivirine drug profile
Table 78: Cabotegravir/rilpivirine Phase III trials in HIV
Table 79: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 80: Fostemsavir drug profile
Table 81: Fostemsavir Phase III trial in HIV
Table 82: Fostemsavir Phase II data in HIV
Table 83: Fostemsavir sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 84: Infectious disease specialists surveyed for the HIV primary research study, 2017
Table 85: Therapies discussed in the HIV key opinion leader primary research study, 2017
Table 86: HIV total infections, new infections, and AIDS-attributable deaths, by region, 2016
Table 87: New HIV diagnoses in the US and five major EU markets, by transmission route, 2016
Table 88: Per-act HIV transmission risk, by transmission route
Table 89: CDC classification system for HIV-infected adults and adolescents
Table 90: Symptomatic conditions included in CDC HIV classification system clinical categories
Table 91: WHO clinical staging of HIV/AIDS for adults and adolescents
Table 92: Treatments available for HIV across the US and five major EU markets
Table 93: Summary of "recommended" treatment options in HHS and EACS treatment guidelines
Table 94: HIV prevalence, infections, and AIDS-attributable deaths in 2017, by region
Table 95: Sources used for the epidemiological analysis of HIV in the US, Japan, and five major EU markets, by country
Table 96: Data sources used to describe the diagnosed prevalent HIV population, by country
Table 97: Data sources used to segment diagnosed incident HIV cases by AIDS at diagnosis, by country
Table 98: Data sources used to segment diagnosed incident HIV cases by transmission category, by country
Table 99: Diagnosed incident cases of HIV in the US, Japan, and five major EU markets, by country, 2018–28
Table 100: Incident cases of HIV diagnosed at AIDS stage, in adults, in the US, Japan, and five major EU markets, by country, 2018
Table 101: Number and proportion of incident HIV cases, by transmission route, and country, 2018
Table 102: Total prevalent cases of HIV in the US, Japan, and five major EU markets, by country, 2018–28
Table 103: Diagnosed and undiagnosed prevalent HIV cases, by country, 2018
Table 104: Co-morbid bone and renal impairments in adult diagnosed prevalent HIV cases, by country, 2018
Table 105: Key marketed drugs for HIV
Table 106: Atripla drug profile
Table 107: Atripla pivotal data in HIV
Table 108: Atripla sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 109: Complera drug profile
Table 110: Complera pivotal data in HIV
Table 111: Complera other late-phase trial data in HIV
Table 112: Complera sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 113: Descovy drug profile
Table 114: Descovy pivotal data in HIV
Table 115: Descovy other late-phase trials in HIV
Table 116: Descovy sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 117: Genvoya drug profile
Table 118: Genvoya pivotal data in HIV
Table 119: Genvoya other late-phase data in HIV
Table 120: Genvoya ongoing late-phase trials in HIV
Table 121: Genvoya sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 122: Isentress drug profile
Table 123: Isentress pivotal data in HIV
Table 124: Isentress sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 125: Juluca drug profile
Table 126: Juluca Phase III data in HIV
Table 127: Juluca sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 128: Odefsey drug profile
Table 129: Odefsey pivotal data in HIV
Table 130: Odefsey other late-phase data in HIV
Table 131: Odefsey sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 132: Prezista drug profile
Table 133: Prezcobix drug profile
Table 134: Prezista pivotal data in HIV
Table 135: Prezista pivotal data in HIV
Table 136: Prezista sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 137: Prezcobix sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 138: Reyataz drug profile
Table 139: Evotaz drug profile
Table 140: Reyataz pivotal data in HIV
Table 141: Reyataz other late-phase data in HIV
Table 142: Reyataz other late-phase data in HIV
Table 143: Reyataz sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 144: Evotaz sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 145: Stribild drug profile
Table 146: Stribild pivotal data in HIV
Table 147: Stribild other late-phase data in HIV
Table 148: Stribild sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 149: Symtuza drug profile
Table 150: Symtuza pivotal data in HIV
Table 151: Symtuza sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 152: Tivicay drug profile
Table 153: Tivicay pivotal data in HIV
Table 154: Tivicay pivotal data in HIV
Table 155: Tivicay ongoing late-phase clinical trials in HIV
Table 156: Tivicay sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 157: Triumeq drug profile
Table 158: Triumeq pivotal data in HIV
Table 159: Triumeq other late-phase data in HIV
Table 160: Triumeq sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 161: Truvada drug profile
Table 162: Truvada pivotal data in HIV
Table 163: Truvada pivotal data in HIV
Table 164: Truvada sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 165: Key Phase III pipeline products in development for HIV
Table 166: B/F/TAF drug profile
Table 167: B/F/TAF Phase III data in HIV
Table 168: B/F/TAF Phase III trials in HIV
Table 169: B/F/TAF sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 170: DOR/3TC/TDF drug profile
Table 171: DOR/3TC/TDF Phase III data in HIV
Table 172: DOR/3TC/TDF Phase III trials in HIV
Table 173: Doravirine Phase III trials in HIV
Table 174: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 175: Tivicay/Epivir drug profile
Table 176: Tivicay/Epivir Phase III trials in HIV
Table 177: Tivicay/Epivir Phase II data in HIV
Table 178: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 179: Cabotegravir/rilpivirine drug profile
Table 180: Cabotegravir/rilpivirine Phase III trials in HIV
Table 181: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Table 182: Fostemsavir drug profile
Table 183: Fostemsavir Phase III trial in HIV
Table 184: Fostemsavir Phase II data in HIV
Table 185: Fostemsavir sales for HIV across the US and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll